r.rotation.to⌕ Search stocks, people, sectors
Following this device: dark.
Request a free account

Follow the people · Insider

JM

Jeffrey A. Meckler

Insider · Director · TVTX

Jeffrey A. Meckler files insider transactions with the SEC as a director of Travere Therapeutics. We hold 2 disclosed purchases and sales filed since 12 July 2012, 1 of them in the last 90 days.

  • Files for 6 companiesTVTX, INDP, NTEC, RTRX and 2 more
  • Disclosed buys and sells2 in all, 1 in the last 90 days
  • Last disclosure11 September 2026

Positions held

6 posts we hold — a term names its own dates; a run of filings only says when they filed
  • Filed 14 May 2021 — 10 September 2026Director · Travere Therapeutics 26 Form 4 lines · source: SEC Form 4
  • Filed 4 August 2021 — 11 February 2026Co-Chief Executive Officer · Indaptus Therapeutics 38 Form 4 lines · source: SEC Form 4
  • Filed 4 April 2019 — 15 July 2020Chief Executive Officer · Intec Pharma 4 Form 4 lines · source: SEC Form 4
  • Filed 8 October 2014 — 15 May 2020Director · Retrophin 17 Form 4 lines · source: SEC Form 4
  • Filed 10 July 2012 — 17 June 2016Director · Qlt Inc/bc 22 Form 4 lines · source: SEC Form 4
  • Filed 11 December 2014 — 15 March 2016Chief Executive Officer · Cocrystal Pharma 8 Form 4 lines · source: SEC Form 4

Every transaction

115 transactions from SEC Form 4 — one row each, sort any column, open a row for the filing
115 of 115 shown
10 Sep 202611 Sep 2026SEC Form 41 dexercised options overnot a tradeTravere Therapeutics10,000 sharesdown −2.0%up +0.0%
10 Sep 202611 Sep 2026SEC Form 41 dexercised options overnot a tradeTravere Therapeutics10,000 sharesdown −2.0%up +0.0%
10 Sep 202611 Sep 2026SEC Form 41 dsold on the open marketTravere Therapeutics1,700 sharesdown −2.0%up +0.0%
10 Sep 202611 Sep 2026SEC Form 41 dsold on the open marketTravere Therapeutics1,200 sharesdown −2.0%up +0.0%
10 Sep 202611 Sep 2026SEC Form 41 dsold on the open marketTravere Therapeutics14,000 sharesdown −2.0%up +0.0%
10 Sep 202611 Sep 2026SEC Form 41 dsold on the open marketTravere Therapeutics3,100 sharesdown −2.0%up +0.0%
10 Sep 202611 Sep 2026SEC Form 41 dexercised options overnot a tradeTravere Therapeuticsderivative10,000 sharesdown −2.0%up +0.0%
10 Sep 202611 Sep 2026SEC Form 41 dexercised options overnot a tradeTravere Therapeuticsderivative10,000 sharesdown −2.0%up +0.0%
19 May 202621 May 2026SEC Form 42 dwas grantednot a tradeTravere Therapeutics4,000 sharesup +56.6%up +47.9%
19 May 202621 May 2026SEC Form 42 dwas grantednot a tradeTravere Therapeuticsderivative12,000 sharesup +56.6%up +47.9%
4 May 20266 May 2026SEC Form 42 dexercised options overnot a tradeTravere Therapeutics8,000 sharesup +47.3%up +47.8%
4 May 20266 May 2026SEC Form 42 dsold on the open marketTravere Therapeutics8,000 sharesup +47.3%up +47.8%
4 May 20266 May 2026SEC Form 42 dexercised options overnot a tradeTravere Therapeuticsderivative8,000 sharesup +47.3%up +47.8%
11 Feb 202613 Feb 2026SEC Form 42 dreturned to the issuernot a tradeIndaptus Therapeuticsderivative3,033 sharesup +55.6%up +57.4%
11 Feb 202613 Feb 2026SEC Form 42 dwas grantednot a tradeIndaptus Therapeuticsderivative3,033 sharesup +55.6%up +57.4%
11 Feb 202613 Feb 2026SEC Form 42 dreturned to the issuernot a tradeIndaptus Therapeuticsderivative1,519 sharesup +55.6%up +57.4%
11 Feb 202613 Feb 2026SEC Form 42 dreturned to the issuernot a tradeIndaptus Therapeuticsderivative3,033 sharesup +55.6%up +57.4%
11 Feb 202613 Feb 2026SEC Form 42 dwas grantednot a tradeIndaptus Therapeuticsderivative3,033 sharesup +55.6%up +57.4%
11 Feb 202613 Feb 2026SEC Form 42 dreturned to the issuernot a tradeIndaptus Therapeuticsderivative1,519 sharesup +55.6%up +57.4%
11 Feb 202613 Feb 2026SEC Form 42 dwas grantednot a tradeIndaptus Therapeuticsderivative1,519 sharesup +55.6%up +57.4%
11 Feb 202613 Feb 2026SEC Form 42 dreturned to the issuernot a tradeIndaptus Therapeuticsderivative12,136 sharesup +55.6%up +57.4%
11 Feb 202613 Feb 2026SEC Form 42 dwas grantednot a tradeIndaptus Therapeuticsderivative12,136 sharesup +55.6%up +57.4%
11 Feb 202613 Feb 2026SEC Form 42 dwas grantednot a tradeIndaptus Therapeuticsderivative1,519 sharesup +55.6%up +57.4%
11 Feb 202613 Feb 2026SEC Form 42 dreturned to the issuernot a tradeIndaptus Therapeuticsderivative12,136 sharesup +55.6%up +57.4%
11 Feb 202613 Feb 2026SEC Form 42 dwas grantednot a tradeIndaptus Therapeuticsderivative12,136 sharesup +55.6%up +57.4%
22 Dec 202529 Dec 2025SEC Form 47 dwas grantednot a tradeIndaptus Therapeutics216,617 sharesup +36.5%up +1.8%
27 Jul 202529 Jul 2025SEC Form 42 dwas grantednot a tradeIndaptus Therapeuticsderivative12,136 sharesdown −72.1%down −70.9%
27 Jul 202529 Jul 2025SEC Form 42 dwas grantednot a tradeIndaptus Therapeutics6,068 sharesdown −72.1%down −70.9%
15 May 202516 May 2025SEC Form 41 dwas grantednot a tradeTravere Therapeuticsderivative19,500 sharesup +212.9%up +293.9%
15 May 202516 May 2025SEC Form 41 dwas grantednot a tradeTravere Therapeutics6,500 sharesup +212.9%up +293.9%
10 Apr 202511 Apr 2025SEC Form 41 dreturned to the issuernot a tradeIndaptus Therapeuticsderivative4,750 sharesdown −79.4%down −79.4%
10 Apr 202511 Apr 2025SEC Form 41 dreturned to the issuernot a tradeIndaptus Therapeuticsderivative3,750 sharesdown −79.4%down −79.4%
10 Apr 202511 Apr 2025SEC Form 41 dreturned to the issuernot a tradeIndaptus Therapeuticsderivative813 sharesdown −79.4%down −79.4%
10 Apr 202511 Apr 2025SEC Form 41 dreturned to the issuernot a tradeIndaptus Therapeuticsderivative1,500 sharesdown −79.4%down −79.4%
10 Apr 202511 Apr 2025SEC Form 41 dreturned to the issuernot a tradeIndaptus Therapeuticsderivative1,563 sharesdown −79.4%down −79.4%
10 Apr 202511 Apr 2025SEC Form 41 dreturned to the issuernot a tradeIndaptus Therapeuticsderivative1,250 sharesdown −79.4%down −79.4%
25 Nov 202426 Nov 2024SEC Form 41 dwas grantednot a tradeIndaptus Therapeuticsderivative42,553 sharesdown −90.4%down −90.5%
25 Nov 202426 Nov 2024SEC Form 41 dwas grantednot a tradeIndaptus Therapeutics42,553 sharesdown −90.4%down −90.5%
9 Oct 202410 Oct 2024SEC Form 41 dwas grantednot a tradeIndaptus Therapeuticsderivative75,000 sharesdown −91.0%down −91.2%
30 Sep 202430 Sep 2024SEC Form 40 dexercised options overnot a tradeTravere Therapeuticsderivative40,000 sharesup +373.0%up +373.0%
30 Sep 202430 Sep 2024SEC Form 40 dexercised options overnot a tradeTravere Therapeutics40,000 sharesup +373.0%up +373.0%
30 Sep 202430 Sep 2024SEC Form 40 dsold on the open marketTravere Therapeutics40,000 sharesup +373.0%up +373.0%
8 Aug 20248 Aug 2024SEC Form 40 dwas grantednot a tradeIndaptus Therapeuticsderivative84,932 sharesdown −94.3%down −94.3%
8 Aug 20248 Aug 2024SEC Form 40 dwas grantednot a tradeIndaptus Therapeutics84,932 sharesdown −94.3%down −94.3%
8 May 202410 May 2024SEC Form 42 dwas grantednot a tradeTravere Therapeuticsderivative19,500 sharesup +870.2%up +950.3%
8 May 202410 May 2024SEC Form 42 dwas grantednot a tradeTravere Therapeutics6,500 sharesup +870.2%up +950.3%
22 Jan 202423 Jan 2024SEC Form 41 dwas grantednot a tradeIndaptus Therapeuticsderivative100,000 sharesdown −94.3%down −94.2%
17 May 202319 May 2023SEC Form 42 dwas grantednot a tradeTravere Therapeuticsderivative13,500 sharesup +286.7%up +302.2%
17 May 202319 May 2023SEC Form 42 dwas grantednot a tradeTravere Therapeutics4,500 sharesup +286.7%up +302.2%
18 Jan 202320 Jan 2023SEC Form 42 dwas grantednot a tradeIndaptus Therapeuticsderivative100,000 sharesdown −93.9%down −94.0%
21 Nov 202222 Nov 2022SEC Form 41 dbought on the open marketIndaptus Therapeutics9,600 sharesdown −94.5%down −94.6%
18 Nov 202222 Nov 2022SEC Form 44 dbought on the open marketIndaptus Therapeutics400 sharesdown −94.5%down −94.6%
8 Sep 202212 Sep 2022SEC Form 44 dbought on the open marketIndaptus Therapeutics10,308 sharesdown −96.2%down −96.5%
7 Sep 20228 Sep 2022SEC Form 41 dbought on the open marketIndaptus Therapeutics8,632 sharesdown −96.2%down −96.2%
6 Sep 20228 Sep 2022SEC Form 42 dbought on the open marketIndaptus Therapeutics1,060 sharesdown −96.0%down −96.2%
6 Jun 20227 Jun 2022SEC Form 41 dbought on the open marketIndaptus Therapeutics19,727 sharesdown −96.3%down −96.1%
11 May 202212 May 2022SEC Form 41 dwas grantednot a tradeTravere Therapeuticsderivative9,000 sharesup +209.5%up +208.6%
11 May 202212 May 2022SEC Form 41 dwas grantednot a tradeTravere Therapeutics3,000 sharesup +209.5%up +208.6%
26 Jan 202228 Jan 2022SEC Form 42 dwas grantednot a tradeIndaptus Therapeuticsderivative200,000 sharesdown −98.0%down −97.8%
18 Nov 202119 Nov 2021SEC Form 41 dbought on the open marketIndaptus Therapeutics11,187 sharesdown −98.2%down −98.2%
14 Sep 202116 Sep 2021SEC Form 42 dbought on the open marketIndaptus Therapeutics12,000 sharesdown −98.6%down −99.1%
4 Aug 20216 Aug 2021SEC Form 42 dwas grantednot a tradeIndaptus Therapeuticsderivative375,000 sharesdown −98.9%down −99.0%
14 May 202118 May 2021SEC Form 44 dwas grantednot a tradeTravere Therapeutics3,000 sharesup +262.2%up +260.6%
14 May 202118 May 2021SEC Form 44 dwas grantednot a tradeTravere Therapeuticsderivative9,000 sharesup +262.2%up +260.6%
15 Jul 202017 Jul 2020SEC Form 42 dwas grantednot a tradeNTECIntec Pharmaderivative300,000 shares——
15 May 202019 May 2020SEC Form 44 dwas grantednot a tradeRetrophinderivative9,000 sharesup +328.8%up +319.9%
15 May 202019 May 2020SEC Form 44 dwas grantednot a tradeRetrophin3,000 sharesup +328.8%up +319.9%
28 Aug 201929 Aug 2019SEC Form 41 dbought on the open marketNTECIntec Pharma20,000 shares——
23 Aug 201927 Aug 2019SEC Form 44 dbought on the open marketNTECIntec Pharma100,000 shares——
8 May 201910 May 2019SEC Form 42 dwas grantednot a tradeRetrophinderivative8,000 sharesup +268.8%up +259.4%
8 May 201910 May 2019SEC Form 42 dwas grantednot a tradeRetrophin2,000 sharesup +268.8%up +259.4%
4 Apr 20195 Apr 2019SEC Form 41 dwas grantednot a tradeNTECIntec Pharmaderivative125,000 shares——
9 May 201811 May 2018SEC Form 42 dwas grantednot a tradeRetrophinderivative10,000 sharesup +149.5%up +151.4%
9 May 201811 May 2018SEC Form 42 dwas grantednot a tradeRetrophin2,500 sharesup +149.5%up +151.4%
17 May 201718 May 2017SEC Form 41 dwas grantednot a tradeRetrophin2,500 sharesup +279.4%up +275.3%
17 May 201718 May 2017SEC Form 41 dwas grantednot a tradeRetrophinderivative10,000 sharesup +279.4%up +275.3%
17 Jun 201621 Jun 2016SEC Form 44 dwas grantednot a tradeQLTIQlt Inc/bcderivative50,000 shares——
17 Jun 201621 Jun 2016SEC Form 44 dwas grantednot a tradeQLTIQlt Inc/bcderivative6,400 shares——
18 May 201619 May 2016SEC Form 41 dwas grantednot a tradeRetrophin2,000 sharesup +305.2%up +307.7%
18 May 201619 May 2016SEC Form 41 dwas grantednot a tradeRetrophinderivative8,000 sharesup +305.2%up +307.7%
15 Mar 201617 Mar 2016SEC Form 42 dbought on the open marketCocrystal Pharma294,118 sharesdown −99.4%down −99.4%
4 Mar 20167 Mar 2016SEC Form 43 dbought on the open marketRetrophin5,000 sharesup +345.0%up +319.3%
3 Mar 20163 Mar 2016SEC Form 40 dbought on the open marketRetrophin10,000 sharesup +355.7%up +355.7%
23 Dec 201528 Dec 2015SEC Form 45 dbought on the open marketCocrystal Pharma100,000 sharesdown −99.4%down −99.4%
1 Oct 20152 Oct 2015SEC Form 41 dwas grantednot a tradeCocrystal Pharmaderivative16,000,000 sharesdown −99.5%down −99.5%
29 Jun 20151 Jul 2015SEC Form 42 dexercised options overnot a tradeQLTIQlt Inc/bc12,500 shares——
29 Jun 20151 Jul 2015SEC Form 42 dexercised options overnot a tradeQLTIQlt Inc/bc12,500 shares——
29 Jun 20151 Jul 2015SEC Form 42 dexercised options overnot a tradeQLTIQlt Inc/bcderivative12,500 shares——
29 Jun 20151 Jul 2015SEC Form 42 dexercised options overnot a tradeQLTIQlt Inc/bcderivative12,500 shares——
8 Jun 201510 Jun 2015SEC Form 42 dwas grantednot a tradeRetrophin2,000 sharesup +103.0%up +106.3%
8 Jun 201510 Jun 2015SEC Form 42 dwas grantednot a tradeRetrophinderivative8,000 sharesup +103.0%up +106.3%
7 Jun 20159 Jun 2015SEC Form 42 dexercised options overnot a tradeQLTIQlt Inc/bc4,000 shares——
7 Jun 20159 Jun 2015SEC Form 42 dexercised options overnot a tradeQLTIQlt Inc/bc6,000 shares——
7 Jun 20159 Jun 2015SEC Form 42 dexercised options overnot a tradeQLTIQlt Inc/bcderivative4,000 shares——
7 Jun 20159 Jun 2015SEC Form 42 dexercised options overnot a tradeQLTIQlt Inc/bcderivative6,000 shares——
25 Mar 201527 Mar 2015SEC Form 42 dbought on the open marketCocrystal Pharma163,043 sharesdown −99.7%down −99.7%
23 Mar 201525 Mar 2015SEC Form 42 dwas grantednot a tradeCocrystal Pharmaderivative1,750,000 sharesdown −99.7%down −99.7%
18 Dec 201419 Dec 2014SEC Form 41 dbought on the open marketQLTIQlt Inc/bc20,000 shares——
17 Dec 201419 Dec 2014SEC Form 42 dwas grantednot a tradeQLTIQlt Inc/bcderivative6,000 shares——
17 Dec 201419 Dec 2014SEC Form 42 dwas grantednot a tradeQLTIQlt Inc/bcderivative12,500 shares——
15 Dec 201417 Dec 2014SEC Form 42 dexercised options overnot a tradeQLTIQlt Inc/bc2,000 shares——
15 Dec 201417 Dec 2014SEC Form 42 dexercised options overnot a tradeQLTIQlt Inc/bcderivative2,000 shares——
11 Dec 201415 Dec 2014SEC Form 44 dbought on the open marketCocrystal Pharma25,000 sharesdown −99.2%down −99.2%
11 Dec 201415 Dec 2014SEC Form 44 dbought on the open marketCocrystal Pharma25,000 sharesdown −99.2%down −99.2%
11 Dec 201415 Dec 2014SEC Form 44 dbought on the open marketCocrystal Pharma50,000 sharesdown −99.2%down −99.2%
25 Nov 201425 Nov 2014SEC Form 40 dbought on the open marketRetrophin15,000 sharesup +636.9%up +636.9%
8 Oct 201410 Oct 2014SEC Form 42 dwas grantednot a tradeRetrophin20,000 sharesup +531.4%up +593.6%
8 Oct 201410 Oct 2014SEC Form 42 dwas grantednot a tradeRetrophinderivative40,000 sharesup +531.4%up +593.6%
22 Nov 201325 Nov 2013SEC Form 43 dwas grantednot a tradeQLTIQlt Inc/bcderivative225,000 shares——
15 Jul 201317 Jul 2013SEC Form 42 dwas grantednot a tradeQLTIQlt Inc/bcderivative11,000 shares——
15 Jul 201317 Jul 2013SEC Form 42 dwas grantednot a tradeQLTIQlt Inc/bcderivative6,000 shares——
15 Jul 201317 Jul 2013SEC Form 42 dwas grantednot a tradeQLTIQlt Inc/bcderivative12,500 shares——
28 Jun 20131 Jul 2013SEC Form 43 dbought on the open marketQLTIQlt Inc/bc30,000 shares——
3 May 20136 May 2013SEC Form 43 dbought on the open marketQLTIQlt Inc/bc20,000 shares——
10 Jul 201212 Jul 2012SEC Form 42 dwas grantednot a tradeQLTIQlt Inc/bcderivative11,000 shares——

Both percentages are the stock’s move, not Jeffrey A. Meckler’s return: a disclosure gives a band, never an amount, so nobody can say how much was bought or what it made. They run to the last close we hold — 11 Sep 2026, except where a name has since delisted, when the row names its own last session. We publish no close, no volume and no dollar figure behind them. 89 of the 115 rows shown carry a percentage; the rest are dashes with the reason on the row.

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.

Some filings reach us as photographs of paper rather than as a form we can read as text. Those are shown here only once they have been read and checked, so this page can hold fewer lines than the filings behind it contain. The link on every row opens the original document, which is always the full record.